GlaxoSmithKline Pharmaceuticals Receives ₹35.07 Lakh GST Demand Order from Maharashtra Authorities

GlaxoSmithKline Pharmaceuticals Limited has informed stock exchanges about receiving a GST demand order from Maharashtra State GST authorities. The pharmaceutical company disclosed this development under Regulation 30 of SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015.

GST Demand Order Details

The company received an order dated December 31, 2025, from the Assistant Commissioner of State Tax, Mumbai, Maharashtra, pertaining to FY 2021-22. The comprehensive breakdown of the demand order is presented below:

Component:	Amount (₹)
Tax:	18,16,196
Interest:	15,10,080
Penalty:	1,81,619
Total Demand:	35,07,895

Nature of Violation

The GST authorities have raised the demand in relation to GST credit-related issues. Specifically, the order addresses mismatches between the company's GST returns and the details reported by its suppliers. This type of discrepancy is a common area of scrutiny by tax authorities during GST assessments.

Company's Response and Impact Assessment

GlaxoSmithKline Pharmaceuticals has clarified that the demand order will have no impact on the company's financial operations. The management is currently evaluating the demand order and has indicated that it will take appropriate actions in due course. This suggests the company may consider filing an appeal or providing additional documentation to address the authorities' concerns.

Regulatory Compliance

The disclosure was made on January 1, 2026, following the company's receipt of the order on December 31, 2025. This timely disclosure demonstrates the company's commitment to maintaining transparency with stakeholders and adhering to regulatory requirements under SEBI guidelines.

The company's proactive approach to addressing the GST demand order reflects its commitment to resolving tax-related matters while ensuring minimal disruption to its business operations.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.11%	-3.41%	-6.77%	-27.25%	+7.43%	+49.47%

GlaxoSmithKline Pharmaceuticals Limited has disclosed receiving a GST demand order from Karnataka State authorities under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The order, dated December 30, 2025, pertains to FY 2021-22 and involves a substantial financial demand.

GST Demand Details

The Deputy Commissioner of Commercial Taxes, (Audit)-2.1, DGSTO-2, Bangalore, has issued the demand order with the following financial breakdown:

Component:	Amount (₹)
Tax:	4,85,42,948.00
Interest:	3,22,93,695.00
Penalty:	48,54,295.00
Total Demand:	8,56,90,938.00

Nature of Violation

The GST authorities have raised the demand in relation to GST rates applied for certain products. The order represents the culmination of an audit process conducted by the Karnataka State GST department for the financial year 2021-22.

Company's Response and Impact Assessment

GlaxoSmithKline Pharmaceuticals has provided the following assessment regarding the demand order:

Parameter:	Details
Financial Impact:	No impact on financial operations
Current Status:	Company is evaluating the demand order
Next Steps:	Will take appropriate actions in due course
Receipt Date:	December 30, 2025

Regulatory Compliance

The disclosure has been made in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates listed companies to inform stock exchanges about material events that could impact their operations or financial position.

The company has communicated this development to both BSE Limited and The National Stock Exchange of India Limited as part of its regulatory obligations. The pharmaceutical company maintains that despite the substantial demand amount, it does not anticipate any immediate impact on its financial operations while it evaluates the order and determines the appropriate course of action.